CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
NCT06254807
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
HER2-positive
Interventions
DRUG:
CT-0525
Sponsor
Carisma Therapeutics Inc